IL-1 inhibitors (IV anakinra 2-10 mg/kg/dose - maximum 100 mg dose), IL-6 inhibitors (tocilizumab 4-8 mg/kg per dose) [7], and convalescent plasma from recovered COVID-19 patients are tried. The gene discussed is IL6; the disease is COVID-19.